DB,
This is what I liked best...
We believe the company will be in a position to report further interim data on the dose-ranging study in the current quarter, followed by full data in mid-2017.
If this happens, it will be an opportunity for the Company to provide more details around the interim trial results and educate the market on the significance of the results!
The trial is expected to be fully recruited by the end of next month- or failing that, they will close recruitment for Part A as they feel they have sufficient information to determine the dose(s) to move forward with.
A.
New NDF Report: DXB, page-5
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |